fondaparinux update... due, page-34

mmmm

Update On Fondaparinux
Alchemia Limited, Brisbane, Australia (ASX:ACL), announces an update on its marketed product, generic fondaparinux, which was launched in the US in July 2011 by its worldwide
marketing partner Dr Reddy’s Laboratories, Inc (DRL).
Alchemia announces that under the terms of the companies’ Collaboration, Development and Marketing Agreement (CDMA), the development costs incurred by Dr Reddy’s have been recouped from sales of fondaparinux. Thus, it is anticipated that for the quarter ended 30 June 2012,
Alchemia will be due its first share of profits arising under the CDMA. By the end of August 2012,
Alchemia expects to receive information regarding the profitability of fondaparinux for the quarter
ending 30 June 2012. After such information is received and agreed, the Company looks forward to
updating the market further.
Commenting on the announcement, Alchemia’s CEO, Pete Smith said, “We are very pleased that
Alchemia will now start to receive its share of profits from fondaparinux. This is a significant
milestone for the company and we look forward to working with Dr Reddy’s to finalise the
numbers.”